• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丘疹性弹性纤维溶解性巨细胞肉芽肿:一例伴单克隆丙种球蛋白病的病例报告,并对他克莫司局部治疗有反应。

Papular elastolytic giant cell granuloma: report of a case associated with monoclonal gammopathy and responsive to topical tacrolimus.

机构信息

Section of Dermatology, DISEM, University of Genoa, Genoa, Italy.

出版信息

Clin Exp Dermatol. 2010 Mar;35(2):145-8. doi: 10.1111/j.1365-2230.2008.03129.x. Epub 2009 Apr 11.

DOI:10.1111/j.1365-2230.2008.03129.x
PMID:19508563
Abstract

Papular elastolytic giant cell granuloma is an unusual variant of annular elastolytic giant cell granuloma. Its rarity makes the assessment of the real efficacy of any treatment difficult, as spontaneous remission is possible. We report a case whose interest, besides the rarity of the occurrence, rests in the pure papular expression of the clinical features, the association with a monoclonal gammopathy and the apparent efficacy of topical tacrolimus.

摘要

丘疹性弹性纤维分解性 giant cell 肉芽肿是环状弹性纤维分解性 giant cell 肉芽肿的一种罕见变异型。由于可能自发缓解,评估任何治疗方法的真正疗效都很困难。我们报告了一例病例,其有趣之处不仅在于其罕见的发生,还在于其临床表现呈单纯丘疹样、与单克隆丙种球蛋白血症相关以及局部他克莫司的明显疗效。

相似文献

1
Papular elastolytic giant cell granuloma: report of a case associated with monoclonal gammopathy and responsive to topical tacrolimus.丘疹性弹性纤维溶解性巨细胞肉芽肿:一例伴单克隆丙种球蛋白病的病例报告,并对他克莫司局部治疗有反应。
Clin Exp Dermatol. 2010 Mar;35(2):145-8. doi: 10.1111/j.1365-2230.2008.03129.x. Epub 2009 Apr 11.
2
Annular erythematous papules in the neckline.领口处的环状红斑丘疹。
Dermatol Online J. 2011 Jan 15;17(1):7.
3
Papular elastolytic giant cell granuloma: a clinical variant of annular elastolytic giant cell granuloma or generalized granuloma annulare?丘疹性弹性组织溶解性巨细胞肉芽肿:环形弹性组织溶解性巨细胞肉芽肿的临床变体还是泛发性环状肉芽肿?
Eur J Dermatol. 1999 Dec;9(8):647-9.
4
Effective treatment with hydroxychloroquine in a case of annular elastolytic giant cell granuloma.羟氯喹治疗环状弹性纤维松解性巨细胞肉芽肿 1 例
Indian J Dermatol Venereol Leprol. 2011 Jan-Feb;77(1):110-1. doi: 10.4103/0378-6323.74988.
5
Papular and reticular elastolytic giant cell granuloma: rapid spontaneous regression.
Acta Derm Venereol. 2007;87(1):89-90. doi: 10.2340/00015555-0189.
6
Papular lesions associated with annular elastolytic giant cell granuloma.与环状弹性组织溶解性巨细胞肉芽肿相关的丘疹性损害。
J Am Acad Dermatol. 1989 Aug;21(2 Pt 2):398-400. doi: 10.1016/s0190-9622(89)80044-1.
7
Spectrum and clinical variants of giant cell elastolytic granuloma.巨细胞弹性组织溶解性肉芽肿的谱系及临床变体
Int J Dermatol. 2017 Jul;56(7):738-745. doi: 10.1111/ijd.13502. Epub 2017 Feb 27.
8
Annular elastolytic giant cell granuloma in an infant: improvement after treatment with oral tranilast and topical pimecrolimus.婴儿环状弹性组织溶解性巨细胞肉芽肿:口服曲尼司特和外用吡美莫司治疗后病情改善
J Am Acad Dermatol. 2005 Nov;53(5 Suppl 1):S244-6. doi: 10.1016/j.jaad.2005.02.013.
9
Successful treatment of annular elastolytic giant cell granuloma with hydroxychloroquine.羟氯喹成功治疗环状弹性组织溶解性巨细胞肉芽肿。
Int J Dermatol. 2013 Apr;52(4):509-11. doi: 10.1111/j.1365-4632.2011.04941.x. Epub 2012 Apr 18.
10
A reticular variant of elastolytic giant cell granuloma.
Clin Exp Dermatol. 2006 Jan;31(1):42-4. doi: 10.1111/j.1365-2230.2005.01926.x.

引用本文的文献

1
A Retrospective Study of 105 Patients with Elastolytic Giant Cell Granuloma and a Proposal for a New Clinical Classification.弹性纤维瘤性巨细胞肉芽肿 105 例回顾性研究及新的临床分类建议。
Acta Derm Venereol. 2022 Mar 28;102:adv00684. doi: 10.2340/actadv.v102.1985.
2
Generalized Acquired Cutis Laxa Associated with Monoclonal Gammopathy of Dermatological Significance.与具有皮肤学意义的单克隆丙种球蛋白病相关的全身性获得性皮肤松弛症。
Case Rep Dermatol Med. 2020 Feb 12;2020:7480607. doi: 10.1155/2020/7480607. eCollection 2020.
3
Generalised papular variant of elastolytic giant cell granuloma.
弹性组织溶解性巨细胞肉芽肿的泛发性丘疹变体。
BMJ Case Rep. 2019 Dec 16;12(12):e231580. doi: 10.1136/bcr-2019-231580.